Global prevalence of Parkinson’s disease is expected to double by 2050, with aging and population growth driving the surge, a ...

Parkinson’s Disease (PD) is one of the most common brain disorders linked to aging, affecting movement and often leading to ...

Global Parkinson’s disease cases are projected to more than double to 25.2 million by 2050, driven largely by aging ...

Parkinson’s disease (PD) affects nearly 2% of adults over 65, making it the second most common neurodegenerative disorder. It ...

April marks Parkinson's Disease Awareness Month, and the American Parkinson Disease Association (APDA) is launching a ...

- Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates ...

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J. Fox Foundation for Parkinson’s ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials-Phase 2/3 ...

Teleneurorehabilitation provides similar improvement in motor and nonmotor symptoms for patients with Parkinson’s disease as ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...